Modeling symptom drivers of oral intake in long-term head and neck cancer survivors
- 84 Downloads
This study examined the relationship between self-reported symptom severity and oral intake in long-term head and neck cancer (HNC) survivors.
An observational survey study with retrospective chart abstraction was conducted. HNC patients who had completed an MD Anderson Symptom Inventory-Head and Neck (MDASI-HN) questionnaire and also had clinician graded oral intake ratings (Functional Oral Intake Scale [FOIS]) were included. Correlation coefficients were computed. FOIS scores were regressed on MDASI-HN symptom items using stepwise backwards elimination for multivariate models.
One hundred and fifty-two survey pairings were included in the analysis (median 44 months follow-up, range 7–198). Per FOIS, 28% of survivors maintained a total oral diet with no restrictions, 67% reported a restricted oral diet (without tube), 3% were partially tube-dependent with some oral intake, and 2% were NPO. Of the 22 symptom items, the most severe items in decreasing order were dry mouth, difficulty swallowing\chewing, problems with mucus, tasting food, and choking/coughing. Significant bivariate correlations, after Bonferroni correction for multiple comparisons, were present for 8 of 22 symptoms with FOIS. On multivariate analysis, symptom severity for difficulty swallowing and problems with teeth/gums remained significantly associated with FOIS.
Oral intake in HNC survivorship is a multidimensional issue and functional outcome that is impacted not only by dysphagia but also by dental status. Symptom drivers of oral intake likely differ in acute survivorship. Nonetheless, these findings highlight the lack of specificity in this end point and also the need for multidisciplinary supportive care to optimize oral intake in survivors.
KeywordsOral intake Head and neck cancer Survivors Symptom drivers Toxicity Functional outcomes
This work was completed with support of the MD Anderson Oro pharynx Program Patient-Reported Outcomes/Function Core.
All listed co-authors performed the following:
1. Substantial contributions to the conception or design of the work or the acquisition, analysis, or interpretation of data for the work
2. Drafting the work or revising it critically for important intellectual content
3 Final approval of the version to be published
4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved
Specific additional individual cooperative effort contributions to study/manuscript design/execution/interpretation, in addition to all criteria above are listed as follows:
MK, MPB, AE—Drafted manuscript and supervised analysis and interpretation of data
KH—Corresponding author; primary investigator; conceived, coordinated, and directed all study activities; responsible for data collection, project integrity, data collection infrastructure, programmatic oversight, direct oversight of classified personnel, manuscript content and editorial oversight and correspondence
GBG, JSL, DIR, QS, TH, CDF—Co-investigators; direct patient care provision, direct toxicity assessment and clinical data collection; interpretation and analytic support
MPB, MK, AE—Data coordination, collection, curation, and analysis
This work was supported in part by infrastructure support from the National Institutes of Health Cancer Center Support (Core) Grant CA016672 to The University of Texas MD Anderson Cancer Center. These listed funders/supporters played no role in the study design, collection, analysis, interpretation of data, manuscript writing, or decision to submit this manuscript for publication. Dr. Hutcheson receives grant support from the Patient-Centered Outcomes Research Institute (PCORI), the MD Anderson Institutional Research Grant Program, and the National Cancer Institute (R03 CA188162). Drs. Fuller and Hutcheson receive funding support from the National Institute for Dental and Craniofacial Research (ROl DE025248 and 1R56DE025248-0l). Dr. Fuller received/receives grant and/or salary support from the National Institutes of Health/National Cancer lnstitute’s Paul Calabresi Clinical Oncology Award Program (K12 CA088084-06) and Clinician Scientist Loan Repayment Program (L30 CA136381-02); the SWOG/Hope Foundation Dr. Charles A. Coltman, Jr., Fellowship in Clinical Trials; the NCI QUBBD (1R01CA225190-01); NCI Early Phase Clinical Trials in Imaging and Image-Guided Interventions Program (1R01CA218148-01); a General Electric Healthcare/MD Anderson Center for Advanced Biomedical Imaging In-Kind Award; an Elekta AB/MD Anderson Department of Radiation Oncology Seed Grant; the Center for Radiation Oncology Research at MD Anderson Cancer Center; and the MD Anderson Institutional Research Grant Program. Family of Paul W. Beach is providing direct salary support for Dr. Kamal.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 2.Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975–2014, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2014/, based on November 2016 SEER data submission, posted to the SEER web site, April 2017
- 3.Mason H, DeRubeis MB, Burke N, Shannon M, Karsies D, Wolf G et al (2016) Symptom management during and after treatment with concurrent chemoradiotherapy for oropharyngeal cancer: a review of the literature and areas for future research. World J Clin Oncol 7:220–226CrossRefPubMedPubMedCentralGoogle Scholar
- 6.Kubrak C, Olson K, Jha N, Jensen L, McCargar L, Seikaly H, Harris J, Scrimger R, Parliament M, Baracos VE (2010) Nutrition impact symptoms: key determinants of reduced dietary intake, weight loss, and reduced functional capacity of patients with head and neck cancer before treatment. Head Neck 32:290–300PubMedGoogle Scholar
- 7.Pauloski BR, Rademaker AW, Logemann JA, Newman L, MacCracken E, Gaziano J, Stachowiak L (2006) Relationship between swallow motility disorders on videofluorography and oral intake in patients treated for head and neck cancer with radiotherapy with or without chemotherapy. Head Neck 28:1069–1076CrossRefPubMedGoogle Scholar
- 20.van den Berg MGA, Rütten H, Rasmussen-Conrad EL, Knuijt S, Takes RP, van Herpen CML, Wanten GJA, Kaanders JHAM, Merkx MAW (2014) Nutritional status, food intake, and dysphagia in long-term survivors with head and neck cancer treated with chemoradiotherapy: a cross-sectional study. Head Neck 36:60–65CrossRefPubMedGoogle Scholar
- 22.Awan MJ, Mohamed ASR, Lewin JS, Baron CA, Gunn GB, Rosenthal DI, Holsinger FC, Schwartz DL, Fuller CD, Hutcheson KA (2014) Late radiation-associated dysphagia (Late-RAD) with lower cranial neuropathy after oropharyngeal radiotherapy: a preliminary dosimetric comparison. Oral Oncol 50:746–752CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Kimura Y, Ogawa H, Yoshihara A, Yamaga T, Takiguchi T, Wada T, Sakamoto R, Ishimoto Y, Fukutomi E, Chen W, Fujisawa M, Okumiya K, Otsuka K, Miyazaki H, Matsubayashi K (2013) Evaluation of chewing ability and its relationship with activities of daily living, depression, cognitive status and food intake in the community-dwelling elderly. Geriatr Gerontol Int 13:718–725CrossRefPubMedGoogle Scholar
- 28.Rosenthal DI, Mendoza T, Cleeland C (2009) Identifying head and neck cancer patients at risk for high symptom burden during treatment. J Clin Oncol 27:15_suppl, 6066Google Scholar
- 32.MD Anderson Head and Neck Cancer Symptom Working Group (2016) Beyond mean pharyngeal constrictor dose for beam path toxicity in non-target swallowing muscles: dose-volume correlates of chronic radiation-associated dysphagia (RAD) after oropharyngeal intensity modulated radiotherapy. Radiother Oncol 118:304–314CrossRefGoogle Scholar